原发性恶性脑肿瘤患者中观察到的免疫缺陷。

Immune defects observed in patients with primary malignant brain tumors.

作者信息

Dix A R, Brooks W H, Roszman T L, Morford L A

机构信息

Department of Microbiology and Immunology, University of Kentucky Medical Center, Lexington 40536-0084, USA.

出版信息

J Neuroimmunol. 1999 Dec;100(1-2):216-32. doi: 10.1016/s0165-5728(99)00203-9.

DOI:10.1016/s0165-5728(99)00203-9

PMID:10695732

Abstract

Malignant glioblastomas (gliomas) account for approximately one third of all diagnosed brain tumors. Yet, a decade of research has made little progress in advancing the treatment of these tumors. In part this lack of progress is linked to the challenge of discovering how glial tumors are capable of both modulating host immune function and neutralizing immune-based therapies. Patients with gliomas exhibit a broad suppression of cell-mediated immunity. The impaired cell-mediated immunity observed in patients with gliomas appears to result from immunosuppressive factor(s) secreted by the tumor. This article reviews what has been elucidated about the immune defects of patients harboring glioma and the glioma-derived factors which mediate this immunosuppression. A model involving systemic cytokine dysregulation is presented to suggest how the immune defects arise in these individuals.

摘要

恶性胶质母细胞瘤（胶质瘤）约占所有确诊脑肿瘤的三分之一。然而，十年的研究在推进这些肿瘤的治疗方面进展甚微。部分而言，这种缺乏进展与发现胶质肿瘤如何既能调节宿主免疫功能又能中和基于免疫的疗法这一挑战有关。胶质瘤患者表现出细胞介导免疫的广泛抑制。在胶质瘤患者中观察到的细胞介导免疫受损似乎是由肿瘤分泌的免疫抑制因子导致的。本文综述了关于患有胶质瘤患者的免疫缺陷以及介导这种免疫抑制的胶质瘤衍生因子的已阐明内容。提出了一个涉及全身细胞因子失调的模型，以说明这些个体中免疫缺陷是如何产生的。